Infant Bacterial Therapeutics AB announced earlier that the Data Monitoring Committee (DMC) performed the planned safety analysis of the study data of 1,403 babies. Company now also received results from the pre-planned futility analysis. The positive outcome of the futility analysis indicates that there is a reasonable, predefined chance that Infant Bacterial Therapeuticsâ AB (IBTâs) Connection Study will achieve a significant therapeutic effect with respect to the primary endpoint, prevention of Necrotizing Enterocolitis (NEC).
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
89.4 SEK | +1.82% | +2.52% | -0.67% |
1st Jan change | Capi. | |
---|---|---|
-0.67% | 108M | |
+3.96% | 70.44B | |
+10.97% | 8.94B | |
-16.83% | 4.75B | |
+43.48% | 4.5B | |
+3.20% | 3.85B | |
-21.36% | 2.34B | |
-29.67% | 2.2B | |
+8.38% | 1.96B | |
+3.90% | 1.65B |
- Stock Market
- Equities
- IBT B Stock
- News Infant Bacterial Therapeutics AB
- Infant Bacterial Therapeutics AB Announces Data Monitoring Committee Performs the Planned Safety Analysis of the Study Data of 1,403 Babies